Is Revolve Group Stock a Buy, Sell or Hold?
Recently, Revolve Group (NYSE:RVLV) management delivered some fairly positive business…
Sell
10
NMTC Quote, Financials, Valuation and Earnings
Last price:
$0.47
Seasonality move
:
-18.81%
Day range:
$0.44 - $0.49
52-week range:
$0.40 - $1.39
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
2.33x
P/B ratio:
4.94x
Volume:
238.3K
Avg. volume:
266.3K
1-year change:
-61.16%
Market cap:
$14.5M
Revenue:
$3.5M
EPS (TTM):
-$0.26
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
NMTC
NeuroOne Medical Technologies
|
-- | -- | 157.41% | -57.14% | -- |
|
BLFS
BioLife Solutions
|
$22.2M | -$0.04 | -17.19% | -96.67% | $31.33 |
|
NTRB
Nutriband
|
$710K | -$0.13 | -- | -- | $13.00 |
|
NVNO
enVVeno Medical
|
-- | -$0.34 | -- | -26.67% | $16.50 |
|
PLSE
Pulse Biosciences
|
-- | -- | -- | -- | -- |
|
SINT
SINTX Technologies
|
$550K | -$5.29 | 20.07% | -96.14% | $300.00 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
NMTC
NeuroOne Medical Technologies
|
$0.47 | -- | $14.5M | -- | $0.00 | 0% | 2.33x |
|
BLFS
BioLife Solutions
|
$21.90 | $31.33 | $1B | -- | $0.00 | 0% | 11.57x |
|
NTRB
Nutriband
|
$4.72 | $13.00 | $52.4M | -- | $0.00 | 0% | 23.14x |
|
NVNO
enVVeno Medical
|
$2.19 | $16.50 | $38.4M | -- | $0.00 | 0% | 201.05x |
|
PLSE
Pulse Biosciences
|
$16.04 | -- | $1.1B | -- | $0.00 | 0% | -- |
|
SINT
SINTX Technologies
|
$1.90 | $300.00 | $4.8M | -- | $0.00 | 0% | 1.19x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
NMTC
NeuroOne Medical Technologies
|
-- | -0.627 | -- | 2.23x |
|
BLFS
BioLife Solutions
|
4.37% | 2.243 | 1.31% | 3.48x |
|
NTRB
Nutriband
|
1.68% | 3.808 | 0.28% | 4.65x |
|
NVNO
enVVeno Medical
|
-- | 0.346 | -- | -- |
|
PLSE
Pulse Biosciences
|
-- | 4.760 | -- | -- |
|
SINT
SINTX Technologies
|
0.82% | 0.462 | 0.68% | 1.91x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
NMTC
NeuroOne Medical Technologies
|
$1.9M | $1.7M | -238.93% | -238.93% | 64.45% | $183.6K |
|
BLFS
BioLife Solutions
|
$8.3M | $1.4M | -5.7% | -6.05% | -147.28% | $583K |
|
NTRB
Nutriband
|
$191K | -$1.4M | -65.19% | -69.58% | -210.38% | -$1.1M |
|
NVNO
enVVeno Medical
|
-- | -$6.7M | -- | -- | -- | -$5.1M |
|
PLSE
Pulse Biosciences
|
-- | -$10.6M | -- | -- | -- | -$9.8M |
|
SINT
SINTX Technologies
|
$38K | -$1.6M | -146.19% | -148.9% | -875.52% | -$1.3M |
NeuroOne Medical Technologies vs. Competitors
-
Which has Higher Returns NMTC or BLFS?
BioLife Solutions has a net margin of 54.53% compared to NeuroOne Medical Technologies's net margin of -363.87%. NeuroOne Medical Technologies's return on equity of -238.93% beat BioLife Solutions's return on equity of -6.05%.
Company Gross Margin Earnings Per Share Invested Capital NMTCNeuroOne Medical Technologies58.85% $0.06 $2.9M BLFSBioLife Solutions-241.56% $0.26 $364.8M -
What do Analysts Say About NMTC or BLFS?
NeuroOne Medical Technologies has a consensus price target of --, signalling upside risk potential of 325.53%. On the other hand BioLife Solutions has an analysts' consensus of $31.33 which suggests that it could grow by 43.08%. Given that NeuroOne Medical Technologies has higher upside potential than BioLife Solutions, analysts believe NeuroOne Medical Technologies is more attractive than BioLife Solutions.
Company Buy Ratings Hold Ratings Sell Ratings NMTCNeuroOne Medical Technologies0 0 0 BLFSBioLife Solutions7 0 0 -
Is NMTC or BLFS More Risky?
NeuroOne Medical Technologies has a beta of 0.692, which suggesting that the stock is 30.823% less volatile than S&P 500. In comparison BioLife Solutions has a beta of 1.933, suggesting its more volatile than the S&P 500 by 93.265%.
-
Which is a Better Dividend Stock NMTC or BLFS?
NeuroOne Medical Technologies has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. BioLife Solutions offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. NeuroOne Medical Technologies pays -- of its earnings as a dividend. BioLife Solutions pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios NMTC or BLFS?
NeuroOne Medical Technologies quarterly revenues are $3.3M, which are larger than BioLife Solutions quarterly revenues of -$3.4M. NeuroOne Medical Technologies's net income of $1.8M is lower than BioLife Solutions's net income of $12.5M. Notably, NeuroOne Medical Technologies's price-to-earnings ratio is -- while BioLife Solutions's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for NeuroOne Medical Technologies is 2.33x versus 11.57x for BioLife Solutions. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income NMTCNeuroOne Medical Technologies2.33x -- $3.3M $1.8M BLFSBioLife Solutions11.57x -- -$3.4M $12.5M
-
Which has Higher Returns NMTC or NTRB?
Nutriband has a net margin of 54.53% compared to NeuroOne Medical Technologies's net margin of -211%. NeuroOne Medical Technologies's return on equity of -238.93% beat Nutriband's return on equity of -69.58%.
Company Gross Margin Earnings Per Share Invested Capital NMTCNeuroOne Medical Technologies58.85% $0.06 $2.9M NTRBNutriband29.58% -$0.12 $11.4M -
What do Analysts Say About NMTC or NTRB?
NeuroOne Medical Technologies has a consensus price target of --, signalling upside risk potential of 325.53%. On the other hand Nutriband has an analysts' consensus of $13.00 which suggests that it could grow by 175.42%. Given that NeuroOne Medical Technologies has higher upside potential than Nutriband, analysts believe NeuroOne Medical Technologies is more attractive than Nutriband.
Company Buy Ratings Hold Ratings Sell Ratings NMTCNeuroOne Medical Technologies0 0 0 NTRBNutriband1 0 0 -
Is NMTC or NTRB More Risky?
NeuroOne Medical Technologies has a beta of 0.692, which suggesting that the stock is 30.823% less volatile than S&P 500. In comparison Nutriband has a beta of 1.049, suggesting its more volatile than the S&P 500 by 4.944%.
-
Which is a Better Dividend Stock NMTC or NTRB?
NeuroOne Medical Technologies has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Nutriband offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. NeuroOne Medical Technologies pays -- of its earnings as a dividend. Nutriband pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios NMTC or NTRB?
NeuroOne Medical Technologies quarterly revenues are $3.3M, which are larger than Nutriband quarterly revenues of $645.8K. NeuroOne Medical Technologies's net income of $1.8M is higher than Nutriband's net income of -$1.4M. Notably, NeuroOne Medical Technologies's price-to-earnings ratio is -- while Nutriband's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for NeuroOne Medical Technologies is 2.33x versus 23.14x for Nutriband. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income NMTCNeuroOne Medical Technologies2.33x -- $3.3M $1.8M NTRBNutriband23.14x -- $645.8K -$1.4M
-
Which has Higher Returns NMTC or NVNO?
enVVeno Medical has a net margin of 54.53% compared to NeuroOne Medical Technologies's net margin of --. NeuroOne Medical Technologies's return on equity of -238.93% beat enVVeno Medical's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital NMTCNeuroOne Medical Technologies58.85% $0.06 $2.9M NVNOenVVeno Medical-- -$0.30 -- -
What do Analysts Say About NMTC or NVNO?
NeuroOne Medical Technologies has a consensus price target of --, signalling upside risk potential of 325.53%. On the other hand enVVeno Medical has an analysts' consensus of $16.50 which suggests that it could grow by 653.43%. Given that enVVeno Medical has higher upside potential than NeuroOne Medical Technologies, analysts believe enVVeno Medical is more attractive than NeuroOne Medical Technologies.
Company Buy Ratings Hold Ratings Sell Ratings NMTCNeuroOne Medical Technologies0 0 0 NVNOenVVeno Medical1 0 0 -
Is NMTC or NVNO More Risky?
NeuroOne Medical Technologies has a beta of 0.692, which suggesting that the stock is 30.823% less volatile than S&P 500. In comparison enVVeno Medical has a beta of 1.040, suggesting its more volatile than the S&P 500 by 3.991%.
-
Which is a Better Dividend Stock NMTC or NVNO?
NeuroOne Medical Technologies has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. enVVeno Medical offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. NeuroOne Medical Technologies pays -- of its earnings as a dividend. enVVeno Medical pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios NMTC or NVNO?
NeuroOne Medical Technologies quarterly revenues are $3.3M, which are larger than enVVeno Medical quarterly revenues of --. NeuroOne Medical Technologies's net income of $1.8M is higher than enVVeno Medical's net income of -$6.2M. Notably, NeuroOne Medical Technologies's price-to-earnings ratio is -- while enVVeno Medical's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for NeuroOne Medical Technologies is 2.33x versus 201.05x for enVVeno Medical. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income NMTCNeuroOne Medical Technologies2.33x -- $3.3M $1.8M NVNOenVVeno Medical201.05x -- -- -$6.2M
-
Which has Higher Returns NMTC or PLSE?
Pulse Biosciences has a net margin of 54.53% compared to NeuroOne Medical Technologies's net margin of --. NeuroOne Medical Technologies's return on equity of -238.93% beat Pulse Biosciences's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital NMTCNeuroOne Medical Technologies58.85% $0.06 $2.9M PLSEPulse Biosciences-- -$0.18 -- -
What do Analysts Say About NMTC or PLSE?
NeuroOne Medical Technologies has a consensus price target of --, signalling upside risk potential of 325.53%. On the other hand Pulse Biosciences has an analysts' consensus of -- which suggests that it could fall by -68.83%. Given that NeuroOne Medical Technologies has higher upside potential than Pulse Biosciences, analysts believe NeuroOne Medical Technologies is more attractive than Pulse Biosciences.
Company Buy Ratings Hold Ratings Sell Ratings NMTCNeuroOne Medical Technologies0 0 0 PLSEPulse Biosciences0 0 0 -
Is NMTC or PLSE More Risky?
NeuroOne Medical Technologies has a beta of 0.692, which suggesting that the stock is 30.823% less volatile than S&P 500. In comparison Pulse Biosciences has a beta of 1.874, suggesting its more volatile than the S&P 500 by 87.435%.
-
Which is a Better Dividend Stock NMTC or PLSE?
NeuroOne Medical Technologies has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Pulse Biosciences offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. NeuroOne Medical Technologies pays -- of its earnings as a dividend. Pulse Biosciences pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios NMTC or PLSE?
NeuroOne Medical Technologies quarterly revenues are $3.3M, which are larger than Pulse Biosciences quarterly revenues of --. NeuroOne Medical Technologies's net income of $1.8M is higher than Pulse Biosciences's net income of -$10.1M. Notably, NeuroOne Medical Technologies's price-to-earnings ratio is -- while Pulse Biosciences's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for NeuroOne Medical Technologies is 2.33x versus -- for Pulse Biosciences. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income NMTCNeuroOne Medical Technologies2.33x -- $3.3M $1.8M PLSEPulse Biosciences-- -- -- -$10.1M
-
Which has Higher Returns NMTC or SINT?
SINTX Technologies has a net margin of 54.53% compared to NeuroOne Medical Technologies's net margin of -882.81%. NeuroOne Medical Technologies's return on equity of -238.93% beat SINTX Technologies's return on equity of -148.9%.
Company Gross Margin Earnings Per Share Invested Capital NMTCNeuroOne Medical Technologies58.85% $0.06 $2.9M SINTSINTX Technologies19.79% -$1.26 $3.9M -
What do Analysts Say About NMTC or SINT?
NeuroOne Medical Technologies has a consensus price target of --, signalling upside risk potential of 325.53%. On the other hand SINTX Technologies has an analysts' consensus of $300.00 which suggests that it could grow by 3584.21%. Given that SINTX Technologies has higher upside potential than NeuroOne Medical Technologies, analysts believe SINTX Technologies is more attractive than NeuroOne Medical Technologies.
Company Buy Ratings Hold Ratings Sell Ratings NMTCNeuroOne Medical Technologies0 0 0 SINTSINTX Technologies0 1 0 -
Is NMTC or SINT More Risky?
NeuroOne Medical Technologies has a beta of 0.692, which suggesting that the stock is 30.823% less volatile than S&P 500. In comparison SINTX Technologies has a beta of 1.124, suggesting its more volatile than the S&P 500 by 12.355%.
-
Which is a Better Dividend Stock NMTC or SINT?
NeuroOne Medical Technologies has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. SINTX Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. NeuroOne Medical Technologies pays -- of its earnings as a dividend. SINTX Technologies pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios NMTC or SINT?
NeuroOne Medical Technologies quarterly revenues are $3.3M, which are larger than SINTX Technologies quarterly revenues of $192K. NeuroOne Medical Technologies's net income of $1.8M is higher than SINTX Technologies's net income of -$1.7M. Notably, NeuroOne Medical Technologies's price-to-earnings ratio is -- while SINTX Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for NeuroOne Medical Technologies is 2.33x versus 1.19x for SINTX Technologies. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income NMTCNeuroOne Medical Technologies2.33x -- $3.3M $1.8M SINTSINTX Technologies1.19x -- $192K -$1.7M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Bloom Energy Stock a Buy, Sell or Hold?
While already interesting as the world moves toward greener energy…
What Do Tesla Delivery Numbers Mean for Tesla Stock?
Tesla (NASDAQ:TSLA) released Q1 delivery numbers, showing a substantial slowdown…
Stock Ideas
Sell
45
Is AAPL Stock a Buy?
Market Cap: $3T
P/E Ratio: 33x
Buy
53
Is MSFT Stock a Buy?
Market Cap: $2.9T
P/E Ratio: 33x
Sell
50
Is NVDA Stock a Buy?
Market Cap: $2.7T
P/E Ratio: 38x
Alerts
Buy
52
RGC alert for Apr 12
Regencell Bioscience Holdings [RGC] is up 29.14% over the past day.
Buy
52
SLP alert for Apr 12
Simulations Plus [SLP] is up 26.73% over the past day.
Buy
89
GDXU alert for Apr 12
MicroSectors Gold Miners 3X Leveraged ETN [GDXU] is up 15.9% over the past day.
